⚕ GalenOps field
←

SITE014-0444

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-09-07

AEs
6
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-27 (study day 5); relationship: Y

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-07 (study day 15); relationship: not assessed

severe serious assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 41); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Colitis — outcome: RECOVERED/RESOLVED; onset 2023-11-11 (study day 50); relationship: Y

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-02-13 (study day 144); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-05-04 (study day 225); relationship: N

Data queries

No data queries.